Archive for the Home Page Category

Nanoscope Therapeutics to Present at Eyecelerator during the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

Nanoscope Therapeutics to Present at Eyecelerator during the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

Nanoscope Therapeutics to Present at Eyecelerator during the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

 

DALLAS, Sept. 26, 2022 — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Dr. Samarendra Mohanty, Co-Founder and President, will give a presentation on the clinical development of Nanoscope’s Multi-Characteristic Opsin (MCO) gene therapy platform at Eyecelerator during the American Academy of Ophthalmology (AAO) 2022 Annual Meeting, taking place Thursday, September 29, 2022, in Chicago, IL.

Pioneering Optogenetic Therapeutics and Optical Gene Delivery for Vision Restoration
Date and Time: Thursday, September 29, 2022; 2:51 p.m. CT
Location: McCormick Place Convention Center

In addition to highlighting the benefits of MCO gene therapy, Dr. Mohanty will profile Nanoscope’s Phase 2b RESTORE trial from its lead clinical program as well as introduce the Company’s groundbreaking non-viral laser-delivered MCO-020 gene therapy for geographic atrophy. RESTORE trial results, along with six-month data from the Phase 2 STARLIGHT trial for Stargardt disease, are expected in H1 2023.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected H1 2023. The company has also fully enrolled a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

SOURCE Nanoscope Therapeutics

Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease

Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease

Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease

Six-month data from Phase 2 STARLIGHT trial expected in H1 2023

DALLASSept. 13, 2022  — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced full enrollment of its Phase 2 clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in blind patients, for Stargardt disease. Six-month data from the Phase 2 STARLIGHT trial are expected in H1 2023.

“We are excited by the therapeutic potential of MCO-010, supported by robust data from previous preclinical and clinical studies,” said Sulagna Bhattacharya, CEO of Nanoscope. “Completing the quick two-month enrollment of this Phase 2 trial, which will evaluate the safety and effects of a single intravitreal injection of MCO-010, brings us another major step forward in developing this novel therapy with broad therapeutic application.”

The Phase 2 STARLIGHT open-label trial (NCT05417126) enrolled six subjects with advanced vision loss due to a clinical or genetic diagnosis of Stargardt disease.  In this study, all subjects received the same single intravitreal dose of 1.2E11gc/eye of MCO-010 as used in the Company’s Phase 2b retinitis pigmentosa (RP) study.

“Stargardt disease is a blinding condition affecting adults and children alike. It is the most common macular dystrophy and has no established treatment,” said Byron Lam, MD, Robert Z. & Nancy J. Greene Chair and Professor of Ophthalmology at the University of Miami and principal investigator in the Phase 2 STARLIGHT trial. “MCO-010 has the potential to improve visual function in RP and Stargardt patients, and we look forward to seeing the data from this study.”

Nanoscope’s optogenetic therapy uses a proprietary AAV2 vector to deliver MCO genes into retinal cells to enable vision in different color environments. The therapy is administered as a single intravitreal injection for in-office delivery without the need for any other devices or interventions. MCO-010 has received orphan drug designations for RP and Stargardt disease from the FDA and is concurrently being evaluated in Nanoscope’s Phase 2b RESTORE trial in patients with RP, with trial results also expected in H1 2023.

About Nanoscope Therapeutics Inc.

Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected H1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

SOURCE Nanoscope Therapeutics

Nanoscope Therapeutics to Present at the 3rd Annual Gene Therapy for Ophthalmic Disorders Meeting

Nanoscope Therapeutics to Present at the 3rd Annual Gene Therapy for Ophthalmic Disorders Meeting

Nanoscope Therapeutics to Present at the 3rd Annual Gene Therapy for Ophthalmic Disorders Meeting

DALLASSept. 8, 2022  — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Dr. Samarendra Mohanty, Co-Founder and President, will give a presentation on the clinical development of Nanoscope’s Multi-Characteristic Opsin (MCO) gene therapy platform and participate in a panel titled “Gene Therapy for Ophthalmic Disorders – A Year in Review” at the 3rd Annual Gene Therapy for Ophthalmic Disorders Meeting, taking place September 13-16, 2022 in Boston, MA.

Details for the presentation are as follows:

Exploring Ambient Light Activatable Optogenetics for Vision Restoration in Retinal Degenerative Diseases
Date and Time: Thursday, September 15, 20229:00-9:30 a.m. ET
Location: DoubleTree by Hilton Boston North Shore

In addition to highlighting the benefits of MCO gene therapy, Dr. Mohanty will detail Nanoscope’s Phase 2b RESTORE trial from its lead clinical program. RESTORE trial results, along with six-month data from the Phase 2 STARLIGHT trial for Stargardt disease, are expected in H1 2023. He will also participate in the panel on Wednesday, September 14, 20228:25-9:05 am ET.

Two other additional technical leaders of Nanoscope, Dr. Subrata Batabyal and Dr. Sanghoon Kim, will be featured in a pre-conference workshop highlighting non-viral spatially targeted, laser gene delivery to retina (details below). Nanoscope’s MCO-020 gene therapy program is based on targeted laser-delivery of optogenes to areas of geographic atrophy in advanced AMD patients, and currently undergoing IND-enabling studies.

Workshop A: Discussing the Use of Non-Viral Gene Delivery as a Therapeutic Modality to the Eye
Date and Time: Tuesday, September 13, 20228:30-11:00 am ET
Location: DoubleTree by Hilton Boston North Shore

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected H1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

 

Nanoscope Therapeutics to Present at Baird’s 2022 Global Healthcare Conference

Nanoscope Therapeutics to Present at Baird’s 2022 Global Healthcare Conference

Nanoscope Therapeutics to Present at Baird’s 2022 Global Healthcare Conference

DALLAS, Sept. 7, 2022  — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that management will present at Baird’s 2022 Global Healthcare Conference on Wednesday, September 14, 2022, in New York.

Chief Executive Officer, Sulagna Bhattacharya, and Chief Medical Officer, Aaron Osborne will present a company update on Nanoscope clinical and corporate activities on Wednesday, September 14, at 12:15 PM Eastern Time in the Morgan Suite (Mezzanine Level). Nanoscope leadership will be available for in-person meetings at the event on both Tuesday, September 13, and Wednesday, September 14.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top-line data expected H1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Nanoscope Announces Presentations at the 22nd Euretina Congress

Nanoscope Announces Presentations at the 22nd Euretina Congress

Nanoscope Announces Presentations at the 22nd Euretina Congress

Results of Phase 2b RESTORE trial for retinitis pigmentosa and six-month data for Phase 2 STARLIGHT trial for Stargardt disease expected in H1 2023

DALLAS, TX (August 29, 2022) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that clinical development of its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in two presentations at the 22nd Euretina Congress, taking place September 1-4, 2022, in Hamburg, Germany and online.

Details for the presentations are as follows:

Development of Novel Endpoints for the Study of Multi-Characteristic Opsin Enabled Vision Restoration in Patients with Advanced Retinitis Pigmentosa; Double-masked, Randomized, sham-controlled, Multicenter Phase 2b study
Presenter: Victor Hugo Gonzalez, M.D., Valley Retina Institute, McAllen, TX.
Session: IRD I
Date and Time: Thursday, September 1, 2022; 3:05 p.m. CEST
Location: Hall X1, Congress Centre Hamburg

Dr. Gonzalez will discuss Nanoscope’s Phase 2b RESTORE trial, its most advanced clinical program. RESTORE trial results, along with six-month data from the Phase 2 STARLIGHT trial for Stargardt disease, are expected in H1 2023.

52 Week Safety and Efficacy of Optogenetic Therapy for Vision Restoration in Retinitis Pigmentosa Patients
Presenter: SriniVas R. Sadda, M.D., President and Chief Scientific Officer of the Doheny Eye Institute, the Stephen J. Ryan – Arnold and Mabel Beckman Endowed Chair, and Professor of Ophthalmology at the University of California – Los Angeles (UCLA), David Geffen School of Medicine.
Session: IRD II
Date and Time: Friday, September 2, 2022; 3:29 p.m. CEST
Location: Hall X1, Congress Centre Hamburg

Dr. Sadda will discuss the safety and efficacy of intravitreal MCO Optogenetic Therapy for vision restoration in advanced retinitis pigmentosa patients in a Phase 1/2a study.

 

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected H1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Nanoscope Therapeutics to Present at the Retina Forum 2022

Nanoscope Therapeutics to Present at the Retina Forum 2022

Nanoscope Therapeutics to Present at the Retina Forum 2022

DALLASAug. 26, 2022 — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Aaron Osborne, Chief Medical Officer, will give a presentation on clinical development of Nanoscope’s Multi-Characteristic Opsin (MCO) gene therapy platform and participate in a panel titled “Gene Therapy Platforms for Macular Disease – Are They Worth the Money?” at the Retina Forum, taking place August 31, 2022, in Hamburg, Germany and online as part of the Ophthalmology Futures Forums.

Details for the presentation are as follows:

Pioneering a New Wave of Optogenetic Therapeutics for Vision Restoration
Presenter: Aaron Osborne, MBBS, Nanoscope’s Chief Medical Officer
Date and Time: Wednesday, August 31, 20224:51 p.m. CEST
Location: The Fontenay Hotel

In addition to highlighting the benefits of MCO gene therapy, Dr. Osborne will detail Nanoscope’s Phase 2b RESTORE trial from its lead clinical program. RESTORE trial results, along with six-month data from the Phase 2 STARLIGHT trial for Stargardt disease, are expected in H1 2023.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected H1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Nanoscope Therapeutics to Move Corporate Headquarters to Dallas

Nanoscope Therapeutics to Move Corporate Headquarters to Dallas

Nanoscope Therapeutics to Move Corporate Headquarters to Dallas

Company focused on unique optogenetic gene therapy to treat blindness

DALLAS, Texas (August 16, 2022) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that it is moving its corporate headquarters to Trinity Towers, in the hub of the Dallas Medical District.

“Moving to Trinity Towers places us in the heart of the growing healthcare community in Dallas,” said Nanoscope Co-Founder and CEO, Sulagna Bhattacharya. “Rapid growth is expected for Nanoscope in 2023 and Trinity Towers provides an excellent space for our expanding team to collaborate.”

Nanoscope’s MCO-010 is an optogenetic therapy delivered as a one-time intravitreal eye injection in an office setting. The therapy uses proprietary vector and promoter technology to deliver the MCO transgene into retinal bipolar cells. These retinal cells become light sensitive, potentially enabling vision in normal light environments.

MCO-010 is currently being evaluated in two clinical trials in the US for the treatment of severe vision loss due to retinitis pigmentosa (RP) and due to Stargardt disease. The Phase 2b multi-center randomized RESTORE trial of MCO-010 for RP is fully enrolled and results are expected in Q1 2023. In addition, the Phase 2 STARLIGHT trial of MCO-010 for Stargardt disease is underway and 6-month data from this multi-center open label study are expected in Q1 2023.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in a Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for RP (NCT04945772) with top line data expected Q1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Media Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com

Nanoscope Therapeutics Announces First Patient Dosed in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease

Nanoscope Therapeutics Announces First Patient Dosed in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease

Nanoscope Therapeutics Announces First Patient Dosed in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease

 

DALLASJuly 25, 2022  — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that the first patient has been dosed in a Phase 2 trial of its Multi-Characteristic Opsin (MCO-010) ambient-light activatable optogenetic monotherapy for Stargardt disease.

“This trial represents the second indication for our vision restoring therapy for people blinded by rare inherited retinal degenerative diseases regardless of gene mutations,” said Sulagna Bhattacharya, CEO of Nanoscope. “Our RESTORE Phase 2b trial for Retinitis Pigmentosa patients has completed enrollment and results are expected in Q1 2023. There are no approved treatments for these debilitating conditions.”

The Phase 2 STARLIGHT open-label trial (NCT05417126) currently has active clinical sites in Texas and Florida and will enroll approximately six patients to receive the same MCO-010 dose of 1.2E11gc/eye as used in the Phase 2b Retinitis Pigmentosa (RP) study. Six-month safety and efficacy data are expected in Q1 2023. Stargardt disease is a progressive, inherited condition affecting children and adults. The condition results in damage to the macula, the central part of the retina responsible for central and detailed vision. Stargardt disease can be caused by several different gene mutations and is the second most common inherited retinal condition after RP.

“Existing experimental treatments for Stargardt primarily aim to slow progression of vision loss. For people who already have advanced vision loss, an optogenetics based approach, such as MCO-010, may have much greater potential to restore lost vision,” Aaron Osborne, CMO and CDO at Nanoscope added.

“MCO-010 offers new hope for individuals with Stargardt macular degeneration. Stargardt patients with severe degeneration typically lack sufficient light sensing photoreceptor neurons needed to qualify for experimental ABCA4 gene specific therapies. Optogenetic therapy may be able to treat a wider group of patients with Juvenile macular degeneration regardless of the status of their light sensing photoreceptor neurons,” said Stephen Tsang, MD, PhD, Laszlo Z. Bito Professor of Ophthalmology, Pathology and Cell Biology at Columbia University Irving Medical Center and advisor to Nanoscope Therapeutics.

Nanoscope’s MCO-010 gene therapy reprograms healthy retinal cells to make them photosensitive. It uses proprietary vector and promoter technology to deliver the MCO genes into retinal bipolar cells enabling vision in different color environments. The therapy involves a single intravitreal injection in a medical office setting.

About Nanoscope Therapeutics Inc.

Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected Q1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Media Contact:

Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

Nanoscope Therapeutics Receives Spotlight in Breakthrough Technologies Award at OIS Retina Innovation Summit

Nanoscope Therapeutics Receives Spotlight in Breakthrough Technologies Award at OIS Retina Innovation Summit

Nanoscope Therapeutics Receives Spotlight in Breakthrough Technologies Award at OIS Retina Innovation Summit

DALLAS, Texas (July 14, 2022) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that the Company was chosen for Breakthrough Technologies Award at OIS Retina Innovation Summit in New York. The award is granted to a single company that demonstrates groundbreaking technological innovation, selected by Medical and Industry Peers.

At the OIS Retina Innovation Summit’s Spotlight on Breakthrough Technologies session, Samarendra Mohanty, Ph.D., Co-Founder, President and Chief Scientific Officer of Nanoscope, gave a presentation on the Company’s Platform technologies on Multi-Characteristic Opsin (MCO) and non-viral laser gene delivery. He also shared progress on U.S. clinical trials of MCO-010 for retinitis pigmentosa and Stargardt disease.

“Amongst the many dedicated industry leaders in the retina space who attended the OIS Retina Innovation Summit, it is an honor for us to be recognized by OIS,” said Nanoscope’s Co-Founder and CEO, Sulagna Bhattacharya. “We are not only encouraged by the progress we are making in advancing our MCO gene therapy platform, but also by the recognition from our industry of our efforts to improve the standard of care for patients suffering from retinal degenerative diseases.”

Results from Nanoscope’s Phase 2b RESTORE trial for retinitis pigmentosa, its most advanced clinical program, along with six-month data from the Phase 2 STARLIGHT trial for Stargardt disease, are expected in Q1 2023.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected Q1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:

Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Media Contact:

Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

Nanoscope’s Gene Therapy to Restore Vision in Patients to be Featured at OIS Retina Innovation Summit and American Society of Retina Specialists Annual Meeting

Nanoscope’s Gene Therapy to Restore Vision in Patients to be Featured at OIS Retina Innovation Summit and American Society of Retina Specialists Annual Meeting

Nanoscope’s Gene Therapy to Restore Vision in Patients to be Featured at OIS Retina Innovation Summit and American Society of Retina Specialists Annual Meeting

Results of Phase 2b RESTORE trial for retinitis pigmentosa and six-month data for Phase 2 STARLIGHT trial for Stargardt disease expected in Q1 2023

DALLAS, July 12, 2022 /PRNewswire/ — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that clinical development of its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in two presentations at the 2022 Annual Scientific Meeting of the American Society of Retina Specialists (ASRS), taking place July 13 – 16, in New York City.

Details for the presentations are as follows:

Update on U.S. Clinical Trials of MCO-010 for Retinitis Pigmentosa and Stargardt Disease and Review of Nanoscope’s Non-viral Laser Gene Delivery Platform
Presenter: Samarendra Mohanty, Ph.D., Nanoscope Co-Founder, President and Chief Scientific Officer
Session: ASRS satellite OIS Retina Innovation Summit, Spotlight on Breakthrough Technologies
Date and Time: Wednesday, July 13, 2022; 4:15 p.m. – 5:15 p.m. ET
Location: Edison Ballroom

Multicenter Randomized Sham-Controlled Double-Masked Phase 2b Clinical Trial of Multi-Characteristic Opsin in Patients with Advanced Retinitis Pigmentosa
Presenter: Peter Kaiser, M.D., FASRS, of the Cole Eye Institute in the Department of Ophthalmology at the Cleveland Clinic
Session: Dry AMD 3 Symposium
Date and Time: Saturday, July 16, 2022; 10:15 a.m. – 11:20 a.m. ET
Location: Javits Center

Dr. Kaiser, a Nanoscope adviser, will discuss Nanoscope’s Phase 2b RESTORE trial, its most advanced clinical program. RESTORE trial results, along with six-month data from the Phase 2 STARLIGHT trial for Stargardt disease, are expected in Q1 2023.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected Q1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Nanoscope’s Top Executive Team to Participate and Present at World Orphan Drug Congress USA Meeting

Nanoscope’s Top Executive Team to Participate and Present at World Orphan Drug Congress USA Meeting

Nanoscope’s Top Executive Team to Participate and Present at World Orphan Drug Congress USA Meeting

Results of Phase 2b RESTORE trial for retinitis pigmentosa and six-month data for Phase 2 STARLIGHT trial for Stargardt disease expected in Q1 2023

 

DALLAS, Texas (July 11, 2022) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that two executive team members will participate and present at the World Orphan Drug Congress, taking place July 11-13, at Hynes Center in Boston.

Details are as follows:

Gene-agnostic Optogenetic therapy for orphan diseases: Overcoming developmental challenges for retinal disease treatments
Presenter: Samarendra Mohanty, Ph.D., Nanoscope President and Chief Scientific Officer
Session: Advanced Therapies Manufacturing,
Date and Time: Tuesday, July 12, 2022; 11:35 a.m. – 11:55 a.m. ET

Dr. Mohanty will discuss Nanoscope’s gene-agnostic optogenetic platform to address need of several orphan diseases. He will also present non-viral laser gene delivery platform for overcoming limitations of viral vector based redosing and delivery of large gene payload. Randomized controlled RESTORE trial results from retinitis pigmentosa patients, along with six-month key data from the Phase 2 STARLIGHT trial from Stargardt patients, are expected in Q1 2023.

Launching of breakthrough products for rare diseases
Chairperson: Michael Marquez, Nanoscope Chief Financial Officer
Session: Advanced Therapies Commercial,
Date and Time: Wednesday, July 13, 2022; 11:05 a.m. – 12:35 p.m. ET

Mr. Marquez will chair a session where key industry leaders will make presentations on commercialization of breakthrough gene and regenerative medicine products for orphan and rare diseases in Global market.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected Q1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Media Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

Nanoscope Therapeutics Appoints Michael Marquez as Chief Financial Officer

Nanoscope Therapeutics Appoints Michael Marquez as Chief Financial Officer

Nanoscope Therapeutics Appoints Michael Marquez as Chief Financial Officer

Dallas, TX (July 05, 2022) — Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, today announced the appointment of Michael Marquez as Chief Financial Officer. Mr. Marquez brings over 17 years of finance experience, including deep experience leading finance and growth strategies for companies in the ophthalmic space.

“Michael’s experience leading finance strategy and initiatives for ocular companies will be valuable as we progress our platform of optogenetic therapies to restore vision in sufferers of inherited retinal degenerative diseases. This appointment strengthens our management team and underscores our evolution as a company,” said Nanoscope’s Co-Founder and CEO, Sulagna Bhattacharya.

“I’m excited to join Nanoscope at this pivotal juncture in its development with its novel approach to treating retinal degenerative disease, supported by compelling data that has been generated thus far for our lead candidate, MCO-010. I believe a robust finance strategy is crucial for the success of any company, and I am looking forward to helping Nanoscope navigate through advanced clinical development and eventually towards commercialization,” said Mr. Marquez.

Mr. Marquez was most recently CFO of TearLab, an ophthalmic diagnostics company with a point-of-care osmolarity test to aid in the diagnosis of dry eye disease. Previously, he served as CFO of Global Surgical at Alcon Laboratories, a global medical company specializing in eye care products. Prior to Alcon, Mr. Marquez worked for Price Waterhouse Coopers serving tax and audit clients in the insurance and manufacturing sectors. He has a Master of Science in accounting from The University of Texas at Arlington and a Bachelor of Business Administration in accounting from The University of Texas at Austin. He is also a licensed Certified Public Accountant in Texas.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The Company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected Q1, 2023. The Company has also initiated a Phase 2 trial of MCO therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. The pipeline also includes therapy for GA.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Media Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

Nanoscope Therapeutics CEO Sulagna Bhattacharya Named Winner of EY Entrepreneur Of The Year® 2022 Central Plains Award

Nanoscope Therapeutics CEO Sulagna Bhattacharya Named Winner of EY Entrepreneur Of The Year® 2022 Central Plains Award

Nanoscope Therapeutics CEO Sulagna Bhattacharya Named Winner of EY Entrepreneur Of The Year® 2022 Central Plains Award

DALLAS, TX (June 27, 2022) —  Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, today announced that CEO and Co-Founder Sulagna Bhattacharya has been named a winner of Ernst & Young’s Entrepreneur Of The Year® 2022 Central Plains Award.

Entrepreneur Of The Year is one of the preeminent competitive business awards for entrepreneurs and leaders of high-growth companies who think big to succeed. An independent panel of judges selected Ms. Bhattacharya based on her entrepreneurial spirit, purpose, growth, and impact, among other core contributions and attributes.

“I am honored to be named a winner in this competition by such a prestigious business organization alongside this dynamic group of business leaders making a difference in their respective fields,” said Ms. Bhattacharya. “This distinction is truly a win for the team at Nanoscope and reflects the passion and ingenuity we bring to work every day. It also underscores the tremendous progress we are making in the clinic advancing our groundbreaking platform of optogenetic therapies to restore vision in people suffering from retinitis pigmentosa and other retinal diseases.”

Entrepreneur Of The Year celebrates entrepreneurs through regional and national awards programs in more than 145 cities in over 60 countries. As a Central Plains award winner, Ms. Bhattacharya will now be considered by the National judges for the Entrepreneur Of The Year 2022 National Awards.

For over 35 years, EY US has celebrated the unstoppable entrepreneurs who are building a more equitable, sustainable and prosperous world for all. Entrepreneur Of The Year Award winners have exclusive, ongoing access to the experience, insight and wisdom of fellow alumni and other members of the entrepreneurial community in over 60 countries — all supported by vast EY resources.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The Company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected Q1, 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients. MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

Nanoscope Therapeutics to Provide Update on Optogenetic Approaches for Vision Restoration at BIO International

Nanoscope Therapeutics to Provide Update on Optogenetic Approaches for Vision Restoration at BIO International

Nanoscope Therapeutics to Provide Update on Optogenetic Approaches for Vision Restoration at BIO International

Dallas, TX (June 13, 2022) — Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, today announced that CEO and Co-Founder Sulagna Bhattacharya will give a Company overview and a clinical update on the Company’s pipeline during the BIO International Convention, being held June 13-16, 2022, in San Diego, CA. The presentation, titled “Pioneering A New Wave of Optogenetic Therapeutics for Vision Restoration,” will take place on June 14, at 4:15 PM PT in Company Presentation Theater 3.

“We will highlight our Multi-Characteristic Opsin gene therapy candidate, MCO-010, which is part of our optogenetics platform for vision restoration in people blinded by retinitis pigmentosa and other retinal diseases,” said Ms. Bhattacharya.

“This is an exciting time for the Company as we advance our clinical programs and expect multiple clinical milestones for MCO-010 over the next 12-months. In the first quarter of 2023, we anticipate reporting both topline Phase 2b RESTORE data results for MCO-010 in patients with retinitis pigmentosa, as well as 6-month data from our open label Phase 2 STARLIGHT trial for patients with Stargardt disease,” continued Ms. Bhattacharya.

Ms. Bhattacharya presently serves on the board of directors of BIO.  She is also a member of the BIO sub-committee for capital formation, advocating for public policy beneficial to small cap and private biotech companies. She will be involved in BIO Board of Directors activities throughout the week.  Additionally, Nanoscope executive team members will be available for meetings to discuss partnering and strategic opportunities.

About Nanoscope Therapeutics Inc.

Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected Q1, 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients. MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

PR Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

Nanoscope’s Clinical Development of Optogenetics for Retinal Diseases to be Featured at Macula Society Meeting

Nanoscope’s Clinical Development of Optogenetics for Retinal Diseases to be Featured at Macula Society Meeting

Nanoscope’s Clinical Development of Optogenetics for Retinal Diseases to be Featured at Macula Society Meeting

DALLAS, Texas (June 6, 2022) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic therapies for treatment of retinal degenerative diseases, today announced two  presentations featuring the Company’s clinical development of optogenetic gene therapy for vision restoration in retinitis pigmentosa (RP) patients at the upcoming 45th Annual Meeting of The Macula Society, to be held June 8-11, 2022, in Berlin, Germany.

“The two abstract presentations will highlight our Multi-Characteristic Opsin gene therapy, MCO-010, for RP, which is part of our optogenetics platform for vision restoration of people blinded by retinal diseases regardless of gene mutations,” said Sulagna Bhattacharya, CEO of Nanoscope. “Our multi-site, double blind, sham-controlled Phase 2b trial in RP patients is fully enrolled with results expected in Q1 2023. We are also initiating a multi-site Phase 2 trial of MCO-010 for Stargardt macular degeneration”

Details for the presentations are as follows:

Title: 52 Week Safety and Efficacy of Optogenetic Therapy for Vision Restoration in Inherited Retinal Degeneration Patients
Session: Inherited Retinal Diseases
Presenter: Sai Chavala, MD, Professor, TCU School of Medicine, Fort Worth, TX. Dr. Chavala is a Nanoscope Scientific and Clinical Advisor.
Date and Time: Wednesday, June 8, 2022, from 6:06 p.m. – 6:52 p.m. CEST

Title: Design and Development of novel endpoints for Double-masked, Randomized, sham-controlled, Multicenter Phase 2b study of Multi-Characteristic Opsin enabled vision restoration in patients with advanced retinitis pigmentosa
Session: Inherited Retinal Diseases
Presenter: Victor Hugo Gonzalez, MD, Valley Retina Institute, McAllen, TX. Dr. Gonzalez is a Nanoscope Scientific and Clinical Advisor.
Date and Time: Saturday, June 11, 2022, from 7:37 – 8:42 a.m. CEST

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing site restoring optogenetic therapies for millions of patients suffering from retinal degenerative diseases.  A Phase 1/2a open label trial (NCT04919473) of Nanoscope’s lead product, MCO-010 in advanced RP patients (n=11), demonstrated a favorable safety profile and several patients experienced restoration of vision to a level sufficient to resume activities of daily living. A multicenter, randomized, double-masked, sham-controlled Phase 2b clinical trial of MCO-010 in RP patients (NCT04945772) is fully enrolled (N=27) and in follow-up. Primary data are expected in H1-2023. The company is initiating Phase-2 clinical trials for Stargardt macular degeneration in Q2-2022. MCO therapy received orphan drug designations from the FDA for RP and Stargardt.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Media Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

Nanoscope Appoints Two Pharmaceutical Industry Veterans as Scientific and Clinical Advisors

Nanoscope Appoints Two Pharmaceutical Industry Veterans as Scientific and Clinical Advisors

Nanoscope Therapeutics Appoints Two Pharmaceutical Industry Veterans as Scientific and Clinical Advisors

Dallas, TX (May 25, 2022) — Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, today announced that Naveed Shams MD, PhD, and Thomas Ciulla MD, both of whom have extensive executive leadership experience at pioneering ophthalmology companies, will serve as advisors to the Company’s Board and Management.

“We are extremely pleased to have these distinguished leaders join our team of advisors. Their deep experience and long list of accomplishments in the ophthalmology space will play a key role in providing guidance to support our clinical and corporate strategy. We look forward to leveraging their expertise as we advance of Nanoscope’s groundbreaking platform of optogenetic therapies,” said Nanoscope’s Co-Founder and CEO, Sulagna Bhattacharya.

“By delivering light-sensitive molecules into retinal cells, Nanoscope is advancing a unique gene therapy approach to restoring vision in people suffering from various inherited retinal degenerative diseases, including Retinitis Pigmentosa (RP), Stargardt, and dry AMD,” said Dr. Shams. “Their unique and creative approach to treating blinding eye diseases and strong clinical data to date shows potential to revolutionize how we treat retinal degenerative diseases and improve patient outcomes. I hope to contribute to the rapid advancement of this platform as the Company completes its ongoing Phase 2b study in RP and looks to rapidly expand into other indications.”

“Multi-Characteristic Opsin, or MCOs, have the potential to address all forms of retinal degeneration and are applicable for patients suffering from complete or partial damage to the retina,” said Dr. Ciulla. “Nanoscope has already begun to demonstrate the tremendous potential of this approach, including extraordinary efficacy and good tolerability in severely visually impaired individuals. I look forward to working with their world-class team in seeing the potential of this approach fully elucidated in the clinic.”

Dr. Shams was most recently the Chief Science Officer at ProQR Therapeutics and previously served as President and CEO of Santen Inc, and Global Head of R&D at Santen Pharmaceuticals, a global ophthalmology company, for over a decade. He has over 25 years of global drug development experience across start-ups and large multinationals, including Novartis and Genentech/Roche. At Genentech, Dr. Shams helped to establish the Ophthalmic Clinical R&D Group and led the development of Lucentis® through approval. Prior to joining industry Dr. Shams was on the Faculty at the Department of Ophthalmology, Harvard Medical School. Dr. Shams holds an MD from Dow Medical College and a PhD in microbiology/immunology from the University of South Carolina. He also completed a fellowship in wound healing and corneal transplantation at Harvard University.

Dr. Ciulla has 25 years of executive management, clinical research and academic leadership experience. He has served as Chief Medical Officer since 2018 and also Chief Development Officer since 2020 at Clearside Biomedical, which pioneered the development of the first FDA-approved suprachoroidal therapy (Xipere®). At Spark Therapeutics, he led medical strategy through approval and commercialization of Luxturna® (voretigene), the first FDA-approved gene therapy for a hereditary retinal disease, which involved novel functional vision endpoints, complex genetic testing paradigms, and new administration procedures. Prior to Spark, he served as VP-Clinical Strategy at Ophthotech (now Iveric Bio), where he contributed to the design of the successful Phase 2/3 trial of Zimura®in Geographic Atrophy (GA). He holds a BA in chemistry from Harvard University, an MD from University of California, San Francisco, Medical School and an MBA from Indiana University. He completed residency at Harvard Medical School, retina fellowship at Tufts Medical School, and is a board-certified ophthalmologist and retina specialist.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected Q1, 2023. The company has also initiated a Phase 2 trial of MCO therapy in Stargardt patients. MCO-010 has received FDA orphan drug designations for RP and Stargardt. The pipeline also includes therapy for GA.

Investor Contact:
Kimberly Minarovich, Sam Martin
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

Nanoscope’s Clinical and Scientific Advances in Optogenetics to be Featured at ASGCT Annual Meeting, May 16-19, 2022 in Washington, DC

Nanoscope’s Clinical and Scientific Advances in Optogenetics to be Featured at ASGCT Annual Meeting, May 16-19, 2022 in Washington, DC

Nanoscope’s Clinical and Scientific Advances in Optogenetics to be Featured at ASGCT Annual Meeting, May 16-19, 2022 in Washington, DC

DALLASMay 13, 2022  — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic therapies for treatment of retinal degenerative diseases, today announced four presentations on the Company’s clinical development and research programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), May 16-19, 2022, at the Walter E. Washington Convention Center in Washington, D.C. The international convention (in-person and virtual) attracts thousands of scientists, patient advocates, physicians, and government officials.

“Nanoscope will be highlighting its MCO-010 clinical gene therapy program that demonstrated vision restoration in people blinded by retinal diseases as well as pioneering nonviral laser delivery of MCO-020 gene therapy for geographic atrophy and optogenetic modulation of neurological disorders,” said Sulagna Bhattacharya, CEO of Nanoscope.

ASGCT will feature two presentations on MCO-010 and two on MCO-020 (all times are U.S. EDT):

Monday, May 163:45 pm – 5:30 pm, Salon H
Synthetic Nanoparticle-Based Gene Transfer oral abstract presentation
In Vivo Spatially Targeted Nonviral Optical Delivery of Genes in Mice to NHPsMonday, May 16, 4:15 – 4:30
pm – Sanghoon Kim, Ph.D.

Monday, May 165:30 pm – 6:30 pm, Hall D
Ophthalmic and Auditory Diseases poster session
Optogenetic Gene Therapy for Treatment of Inherited Retinal Disorders in a Gene Agnostic Manner [Board No.
M-174]
 – Subrata Batabyal, Ph.D.

Neurologic Diseases I poster session
Optogenetic Modulation of the Central Nervous System for Pain [Board No. M-152] – Darryl Narcisse, M.D.

Tuesday, May 175:30 pm – 6:30 pm, Hall D
Gene and Cell Therapy Trials in Progress poster session
AAV Intravitreal Optogenetic Therapy for Vision Restoration in Patients with Severe Retinal Dystrophy [Board
No. Tu-306]
 – Samarendra Mohanty, Ph.D.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing optogenetic therapies to give sight to millions of patients suffering from retinal degenerative diseases. Nanoscope’s lead product, MCO-010, is an investigational AAV gene therapy designed to restore functional vision to patients with severe vision loss due to retinal degeneration. In a Phase 1/2a open label trial (NCT04919473) of MCO-010 in patients with advanced RP (n=11), MCO-010 demonstrated a favorable safety profile and several patients experienced restoration of vision to a level sufficient to resume activities of daily living. A multicenter, randomized, double-masked, sham-controlled Phase 2b clinical trial of MCO-010 for treatment of RP (NCT04945772) is fully enrolled (N=27) and in follow-up. Primary data are expected in H1-2023. The company is initiating Phase-2 clinical trials for Stargardt macular degeneration in Q2-2022. MCO therapy received orphan drug designations from the FDA for RP and Stargardt.

Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

Nanoscope’s Vision-Restoring Optogenetic Gene Therapy to be Featured in Multiple Presentations as Part of ARVO Annual Meeting in Denver May. 1-4, 2022

Nanoscope’s Vision-Restoring Optogenetic Gene Therapy to be Featured in Multiple Presentations as Part of ARVO Annual Meeting in Denver May. 1-4, 2022

Nanoscope’s Vision Restoring Optogenetic Gene Therapy to be Featured in Multiple Presentations as Part of ARVO Annual Meeting in Denver May 1-4, 2022

DALLAS, Texas (April 26, 2022) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic therapies for treatment of retinal degenerative diseases, today announced four presentations on the Company’s preclinical and clinical research in retinitis pigmentosa (RP) and Stargardt macular degeneration at the Association for  Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting, being held May 1 – 4, 2022, in Denver, Colorado.

“We are excited to showcase the breadth and depth of our gene therapy programs from creating disease models to mutation-agnostic gene therapy, and novel instrumentation for assessing retinal function and functional vision in pre-clinical models and in the clinic,” said Sulagna Bhattacharya, CEO of Nanoscope “Our presentations highlight our efforts to address outer retinal degenerative diseases with the goal of bringing relief to the millions of patients worldwide.”

Nanoscope presentations at ARVO-2022:

AAV-carried MCO Optogenetic Therapy for the Treatment of Inherited Retinal Disorders

Presenter: Subrata Batabyal, Ph.D.
Date/Time: May 1, 2022; 12:15 PM – 2:15 PM MDT
Location: A0047, Poster Hall

Double-masked, Randomized, sham-controlled, Multicenter Phase 2b study of Multi-Characteristic Opsin enabled vision restoration in patients with advanced retinitis pigmentosa: Design and Development of novel endpoints

Presenter: Samarendra Mohanty, Ph.D.
Date/Time: May 2, 2022; 12:30 PM – 2:30 PM MDT
Location: F0040, Poster Hall

Establishing a novel preclinical laser-induced model for regenerative therapies of the outer retina

Presenter: Silvia Aparicio Domingo, MS.
Date/Time: May 2, 2022; 1:00 PM – 3:00 PM MDT
Location: F0399, Poster Hall

OCT-guided variable-spot ERG enabled spatially resolved measurements to assess retinal function in a selected and integrated region

Presenter: Sanghoon Kim, Ph.D.
Date/Time: May 4, 2022; 11:08 AM – 11:25 PM MDT
Location: 4EF, Mile High Ballroom

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing optogenetic therapies to give sight to millions of patients suffering from retinal degenerative diseases. Nanoscope’s lead product, MCO-010, is an investigational AAV gene therapy designed to restore functional vision to patients with severe vision loss due to retinal degeneration. In a Phase 1/2a open label trial of MCO-010 in patients with advanced RP (n=11), MCO-010 demonstrated a favorable safety profile and several patients experienced restoration of vision to a level sufficient to resume activities of daily living.  A multicenter, randomized, double-masked, sham-controlled Phase 2b clinical trial of MCO-010 for treatment of RP (NCT04945772) is fully enrolled (N=27) and in follow-up. Primary data are expected in H1-2023. The company will begin Phase-2 clinical trials for Stargardt macular degeneration in Q2-2022. MCO therapy received orphan drug designations from the FDA for RP and Stargardt.

 

Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186
  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Samar obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs international conference on optogenetics. He is winner of 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.